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C9ORF72 repeat expansion causes vulnerability of
motor neurons to Ca2+-permeable AMPA receptor-
mediated excitotoxicity
Bhuvaneish T. Selvaraj et al.#
Mutations in C9ORF72 are the most common cause of familial amyotrophic lateral sclerosis
(ALS). Here, through a combination of RNA-Seq and electrophysiological studies on induced
pluripotent stem cell (iPSC)-derived motor neurons (MNs), we show that increased
expression of GluA1 AMPA receptor (AMPAR) subunit occurs in MNs with C9ORF72
mutations that leads to increased Ca2+-permeable AMPAR expression and results in
enhanced selective MN vulnerability to excitotoxicity. These deﬁcits are not found in iPSC-
derived cortical neurons and are abolished by CRISPR/Cas9-mediated correction of the
C9ORF72 repeat expansion in MNs. We also demonstrate that MN-speciﬁc dysregulation of
AMPAR expression is also present in C9ORF72 patient post-mortem material. We therefore
present multiple lines of evidence for the speciﬁc upregulation of GluA1 subunits in human
mutant C9ORF72 MNs that could lead to a potential pathogenic excitotoxic mechanism in
ALS.
DOI: 10.1038/s41467-017-02729-0 OPEN
Correspondence and requests for materials should be addressed to D.J.A.W. (email: david.j.a.wyllie@ed.ac.uk)
or to S.C. (email: siddharthan.chandran@ed.ac.uk). #A full list of authors and their afﬂiations appears at the end of the paper.
NATURE COMMUNICATIONS |  (2018) 9:347 |DOI: 10.1038/s41467-017-02729-0 |www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
ALS is a relentlessly progressive and invariably fatal neu-rodegenerative disorder characterized by the selectivedeath of MNs. Recognition that familial and sporadic ALS
are largely phenotypically indistinguishable and share pivotal
pathological features highlights the value of the study of familial
ALS to shed mechanistic insight into ALS. Expansion of a
GGGGCC (G4C2) intronic hexanucleotide in the C9ORF72 gene
is the most common cause of familial ALS and accounts for ∼10%
of sporadic ALS cases1,2.
Although the precise underlying mechanisms of cell-type
speciﬁcity and death is unknown in ALS, enhanced MN vulner-
ability to glutamate-mediated excitotoxicity leading to intracel-
lular Ca2+ overload has been implicated3–7. Rodent studies have
suggested that stoichiometry of AMPAR subunits is central to
excitotoxicity noting that GluA1, 3, and 4 AMPAR subunits are
Ca2+-permeable and that GluA2 subunit typically is Ca2
+-impermeable8–14. Inefﬁcient RNA editing of the GluA2 subunit,
resulting in Ca2+-permeability, in sporadic ALS patient samples
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Fig. 1 Excision of the G4C2 repeat expansion. a Strategy for generating C9-Δ from iPSC harboring G4C2 repeat expansion mutation. Two gRNAs were
designed ﬂanking the G4C2 repeats in intron-1 of the C9ORF72 gene to generate a double-strand break (depicted by //). b PCR of the G4C2 locus in HEK-
293 cells transfected with Cas9-gRNA-1 and 2 plasmids generated truncated PCR product (blue arrow) depicting both gRNAs are functional. c Repeat
primed PCR and PCR ﬂanking G4C2 locus showed absence of hexanucleotide repeat expansion in C9-Δ iPSC. d Southern blot analysis of C9ORF72 alleles in
control, mutant C9ORF72, and C9-Δ iPSC lines. e Sanger sequencing of G4C2 locus in C9ORF72 gene-edited lines conﬁrmed excision of hexanucleotide
repeat expansion in mutant allele. G4C2 repeats in wild-type allele were also excised by CRISPR/Cas9 editing strategy (C9-1: 6 repeats, C9-2: 2 repeats,
C9-3: 1 repeat)
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Fig. 2 Excision of the G4C2 repeat expansion reverses RNA foci pathology in mutant MNs. a Schematic representation of MN generation and timings of
various experiments performed. b Representative images of Isl1/2 and Tau immunostainings in 1-week-old MNs (scale bar: 50 µm). c Percentage of Isl1/2+
MNs from various iPSC lines (data represented as mean± s.e.m., Con-1, N= 3; Con-2, N= 3; C9-1, N= 3; C9-1Δ, N= 3; C9-2, N= 3; C9-2Δ, N= 2; C9-3,
N= 3; C9-3Δ, N= 3). d RNA ﬂuorescent in situ hybridization showed mutant C9ORF72 MNs exhibit intra-nuclear RNA foci (scale bar: 5 µm). e
Representative dot-blots for poly-GA, poly-GP, and poly-GR DPRs in mutant C9ORF72 MNs. RA retinoic acid, SAG smoothened agonist, DAPT
N-[N-(3,5-Diﬂuorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester, BDNF Brain-derived neurotrophic factor
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further highlights the importance of improved understanding of
the role of AMPARs in ALS15,16.
A powerful approach to interrogate the consequences of G4C2
expansion in human MNs is the study of iPSC-derived MNs from
ALS patients carrying the C9ORF72 mutation17,18. Generation of
isogenic lines using gene editing technologies, where the only
variable is the mutation of interest, thus allowing direct causality
to be assigned to any phenotype, further extends the biological
relevance of iPSC studies19–22. In this study, we have used
CRISPR/Cas9 technology to excise G4C2 repeats from ALS
patient-derived MNs to enable direct study of the pathogenic role
of G4C2 repeats with particular reference to AMPAR-mediated
excitoxicity. We show that mutant C9ORF72 MNs exhibit
increased GluA1 AMPAR expression leading to enhanced
MN-speciﬁc vulnerability to excitoxicity. This vulnerability is
abolished by CRISPR/Cas9-mediated correction of the C9ORF72
repeat expansion in MNs. Finally, we demonstrate that AMPAR
expression is also selectively dysregulated in spinal cord, but not
cortical, post-mortem tissue from patients harboring C9ORF72
repeat expansions.
Results
Gene targeting and correction of the C9ORF72 mutation. A
CRISPR/Cas9-mediated targeting strategy was used to correct the
mutation in three independent C9ORF72 iPSC lines. Two
CRISPR guide (g) RNAs (gRNA-1 and gRNA-2) were engineered
to target either side of the G4C2 repeats in the intron1 of the
C9ORF72 gene. We selected gRNAs that have at least three
mismatches to potential off-target sites, which are highly homo-
logous to on-target sites. In the absence of a repair template the
double-strand breaks were religated by non-homologous end
joining resulting in deletion of G4C2 repeats (Fig. 1a). First,
gRNAs (1 and 2) along with Cas9 plasmid were transfected in
HEK-293 cells, which have 3 × G4C2 repeats, to test if the gRNAs
were functional. PCR ampliﬁcation of G4C2 locus in control
HEK-293 cells generated a 420 bp amplicon, whereas HEK-293
cells transfected with gRNAs and Cas9 generated both an une-
dited 420 bp amplicon (red arrowhead) and a truncated PCR
amplicon (blue arrowhead) suggesting both gRNAs were able to
target and delete G4C2 repeats (Fig. 1b). Given that the gRNAs
were functional, we next nucleofected Cas9 and gRNAs (1 and 2)
into the mutant C9ORF72 iPSC lines that harbor G4C2 repeats
(C9-1, up to ~638 repeats; C9-2, up to ~960 repeats; C9-3, up to
~760 repeats; Supplementary Fig. 1A). Repeat primed PCR and
G4C2 locus PCR were used to screen individual single-cell-derived
clones. PCR of G4C2 locus in mutant C9ORF72 iPSCs lines
yielded a single amplicon of ~420–450 bp from the wild-type
allele (C9-1, 8 repeats; C9-2, 2 repeats; C9-3, 2 repeats). The
mutant allele is not ampliﬁed due to larger amplicon size. Dele-
tion of the repeat expansion by CRISPR/Cas9 yields additional
PCR amplicons (Fig. 1c). Efﬁciency of deletion of G4C2 repeats
varied between the different iPSC lines ranging from 0.6–4.5%
(C9-1, 2.27%; C9-2, 4.5%; C9-3, 0.6%). For each mutant C9ORF72
iPSC line, we selected 1 clone that was conﬁrmed by repeat
primed PCR to have a lack of G4C2 repeats. All such lines are
hereafter termed C9-1Δ, C9-2Δ, and C9-3Δ (Fig. 1c). In all three
C9ORF72 repeat expansion edited lines the wild-type allele was
also modiﬁed since we observed truncated PCR amplicons
(Fig. 1c). Southern blot analysis using a probe outside the G4C2
repeats conﬁrmed absence of repeat expansion in the positive
clone (Fig. 1d). We further sequenced the G4C2 locus of both the
alleles in the positive clones to determine the deleted sequence.
C9-1Δ contains 2 × G4C2 repeats in both alleles; C9-2Δ contains
1 × G4C2 repeat in one allele and absence of G4C2 repeat in other
allele; and C9-3Δ contains 2 × G4C2 repeats in one allele and 1
G4C2 repeat in the other allele (Fig. 1e). This conﬁrmed that the
gene-corrected iPSC clone was karyotypically normal (Supple-
mentary Fig. 1B) and retained pluripotency markers such as
OCT3/4, TRA-1-60 (Supplementary Fig. 1C). RNA-guided gen-
ome editing, although efﬁcient, has higher off-target activity when
compared to other genome editing tools23. Assessment of highest
candidate off-target sites, two for gRNA-1 and two for gRNA-2,
by Sanger sequencing conﬁrmed no off-target activity for the
chosen gRNAs in all three mutant C9ORF72 iPSC lines (Sup-
plementary Fig. 1D).
C9ORF72 mutant MNs display RNA foci. Having corrected the
mutation, we next generated, using a recently reported protocol24,
MNs from two unrelated healthy controls (Con-1, Con-2) and
from three patients harboring the C9ORF72 mutation (C9-1,
C9-2, C9-3) and their isogenic pairs (C9-1Δ, C9-2Δ, C9-3Δ)
(Fig. 2a). All lines efﬁciently differentiated into highly enriched
neuronal cultures (>95% Tau+, devoid of astrocytes) that
expressed the MN markers Isl1/2 (40–60%) and ChAT at 1 and
3 weeks post-plating, respectively (Fig. 2b, c; Supplementary
Fig. 2A, B). Three principal hypotheses have been proposed to
explain how mutant C9ORF72 is pathogenic: haploinsufﬁciency
leading to reduced levels of C9ORF72 protein, RNA foci binding
essential RNA-binding proteins, and direct toxicity of dipeptide
repeats (DPR) generated by repeat-associated non-ATG (RAN)
translation of G4C2 repeats25. To evaluate whether expansion
results in loss of protein, western blot analysis was undertaken.
This revealed comparable amounts of C9ORF72 protein expression
in MNs derived from all control, mutant, and gene-corrected iPSC
lines (Supplementary Figs. 2C, 8B). Intranuclear RNA foci in MNs
are a characteristic pathological ﬁnding in post-mortem tissue of
C9ORF72 patients1. Using ﬂuorescent in situ hybridization we
conﬁrmed abundant intranuclear RNA foci in mutant MNs that
were absent in controls and gene-corrected lines (Fig. 2d) and
absent in RNAse-treated cultures. Recent reports have observed
DPRs in mutant C9ORF72 material and indeed protein lysates
from mutant C9ORF72 MNs expressed higher levels of GA, GP,
and GR RAN peptides when compared to control and gene-
corrected MNs (Fig. 2e). Collectively, these ﬁndings demonstrate a
direct causal link between C9ORF72 mutation and the presence of
intranuclear foci and RAN peptides. Next, we undertook survival
analysis to determine if the C9ORF72 mutation confers selective
cellular vulnerability on MNs under basal conditions. Survival,
measured using either single-cell longitudinal analysis or absolute
cell counts, showed no difference between control and mutant
MNs (Supplementary Fig. 2D). Thus, although mutant MNs dis-
play pathological RNA foci and DPRs these do not impact upon
cell viability or survival under basal conditions.
Mutant C9ORF72MNs display no difference in excitability. We
and others have previously shown that mutant C9ORF72 iPSC-
derived MNs exhibit differences in excitability when using dif-
ferentiation protocols which result in mixed cultures of neurons
and glia17,26,27. In the present study using distinct protocols that
produce neuronal only, MN-enriched cultures, whole-cell patch-
clamp recordings of MNs were undertaken to assess their ﬁring
properties (Fig. 3a). No signiﬁcant differences were observed in
the proportions of ﬁring types (Fig. 3b) or intrinsic properties
(Supplementary Table 1) of MNs derived from control or mutant
iPSCs. Frequency–current (F–I) relationships were also compar-
able between control and mutant C9ORF72 MNs (Fig. 3c, d;
Supplementary Table 1). Collectively, these ﬁndings reveal no
difference in excitability between control and mutant C9ORF72
MNs in MN-enriched cultures lacking glial cells and therefore
implicate aberrant neuron–glia interactions in the functional
deﬁcits reported previously17,26,27.
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Altered GluA1 subunit expression in mutant C9ORF72 MNs.
To begin to understand the molecular consequences of C9ORF72
mutation on MNs, we next undertook RNA-Seq analysis. Hier-
archical clustering and heat map analysis showed segregation
between control (including MN from an isogenic line, C9-3Δ)
and mutants (C9-1, C9-3) (Fig. 4a). The high degree of similarity
between C9-3 and C9-3Δ further indicates comparison between
isogenic control overcomes the transcriptional heterogeneity
observed in different iPSC lines and observed differential
expression is driven by the mutation (Fig. 4a). We ﬁltered dif-
ferentially expressed genes using the following stringent criteria:
(1) genes must have signiﬁcant differential expression in both
independent mutant C9ORF72 lines (p< 0.05) when compared to
independent control lines, (2) there must be signiﬁcant difference
between C9-3 and C9-3Δ (p< 0.05), and (3) no signiﬁcant dif-
ference observed between C9-3Δ and controls (p> 0.05). Using
this approach 85 upregulated and 80 downregulated genes, col-
lectively 165, were identiﬁed (Fig. 4b, c, d; Supplementary Data 1,
2). Gene ontology analysis revealed that genes involved in RNA
processing, protein targeting, nuclear transport, and ion transport
were signiﬁcantly upregulated in mutant C9ORF72 MNs. Among
downregulated genes in mutant C9ORF72 MNs there was
enrichment for genes involved in synaptic transmission,
cell–cell signaling, and regulation of phosphate metabolism
(Fig. 4f, g).
The ﬁnding that the GluA1 subunit was signiﬁcantly upregu-
lated (>2-fold) in C9ORF72 MNs (red star, Fig. 4d) is consistent
with multiple lines of evidence implicating dysregulation of
glutamate receptor homeostasis in the pathogenesis of ALS28.
RNA-Seq analysis of the other AMPAR subunits and their
auxiliary subunits showed that only GluA1 mRNA was differen-
tially expressed in mutant C9ORF72 MNs (Supplementary Fig. 3).
Subsequent RT-qPCR conﬁrmed increased expression of GluA1 in
all week 3 mutant C9ORF72 MNs with gene-corrected lines
showing reversal to control levels. Moreover, we also observed
increases in GluA3 mRNA expression in mutant C9ORF72 MNs
for two out of the three lines examined (Fig. 5a). Western blot
analysis also conﬁrmed increased levels of GluA1 in all week 3
mutant C9ORF72 MNs with gene-corrected lines displaying levels
comparable to controls (Fig. 5b, c; Supplementary Fig. 8A).
Importantly, relative expression of GluA2 mRNA was not altered
in any of the lines (Fig. 5a). As would be expected, given the
neuronal maturation proﬁle of AMPAR subunit composition29,
we did not observe altered expression of Ca2+-permeable AMPAR
subunits in week 1 MNs (Supplementary Fig. 4A).
The increased proportion of Ca2+-permeable AMPARs in
mutant MNs at week 3 could also be due to inefﬁcient RNA
editing of GluA2 subunit in addition to increased expression of
non-GluA2 subunits. We found, however, that GluA2 subunits
were efﬁciently RNA-edited in all mutant cultures (Fig. 5d;
Supplementary Fig. 4B). Together, these ﬁndings demonstrate
that mutant C9ORF72 MNs exhibit an increased expression of
Ca2+-permeable GluA1 AMPAR subunits, but not inefﬁcient
editing of the GluA2 subunit.
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Fig. 3 Excitability of MNs derived from mutant C9ORF72 patient and control iPSCs. a Evoked ﬁring types observed in iPSC-derived MNs. MNs displayed
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Mutant C9ORF72 MNs are more vulnerable to excitotoxicity.
To determine whether the observed changes in the AMPAR
subunit expression proﬁles had physiological consequences we
next examined whether week 3 mutant MNs exhibited enhanced
relative functional expression of Ca2+-permeable AMPARs. MNs
from all lines expressed robust AMPA-evoked currents that were
potentiated by the allosteric modulator, cyclothiazide, and
blocked by AMPAR antagonist CNQX (Supplementary Fig. 5A).
The presence of one or more edited GluA2(R) subunits in the
AMPAR complex confers Ca2+-impermeability, reduced single-
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channel conductance, and reduced sensitivity to channel-blocking
polyamines29,30. We assessed the proportion of Ca2+-permeable
AMPARs in MNs by measuring the block of AMPAR-mediated
currents by NASPM, a selective blocker of Ca2+-permeable
AMPARs (Fig. 6a, b), and estimated their mean single-channel
conductance using non-stationary ﬂuctuation analysis (Fig. 6c, d).
Comparison of weeks 1 and 3 control MNs showed a reduction in
both mean NASPM block and single-channel conductance that is
consistent with a transition to a predominantly Ca2+-imperme-
able AMPAR population (Fig. 6b, d) and the maturation of
AMPAR composition in native MNs29. In contrast, mutant
C9ORF72 MNs at week 3 retained both a high sensitivity to
NASPM block and an elevated single-channel conductance con-
sistent with persistent expression of Ca2+-permeable AMPARs
(Fig. 6b, d). Strikingly, the maturation of AMPAR composition in
C9-1Δ, C9-2Δ, and C9-3Δ MNs reﬂected that of control MNs.
Importantly the retention of Ca2+-permeable AMPARs in mutant
C9ORF72 MNs was not due to a slower maturation of AMPAR
composition as prolonging culture times for a further 2 weeks did
not reveal any changes in the biophysical properties of AMPARs
(Fig. 6b, d). Furthermore, we did not observe any impairment in
the maturation of intrinsic properties or excitability of MNs across
all lines, indicating that AMPAR-mediated-induced ﬁring is
unlikely to be a differential source of excitotoxicity in our cultures.
These data demonstrate that the C9ORF72 mutation increases
persistence in the relative expression of Ca2+-permeable AMPARs.
Given the alteration in AMPAR composition we next
examined whether C9ORF72 patient-derived MNs showed
increased vulnerability to AMPA-induced excitotoxicity. Expo-
sure to AMPA resulted in greater levels of cell death in week 3,
but not week 1, mutant C9ORF72 MN cultures vs. control and
C9-Δ cultures (Fig. 6e, f; Supplementary Fig. 5B, C). Importantly,
enhanced susceptibility of mutant C9ORF72 MNs to excitotoxi-
city was not due to elevated AMPAR current ﬂux as evidenced by
no differences in AMPA-mediated current densities in each of the
cell lines at week 3 (Supplementary Fig. 5D). Excitotoxicity
experiments performed in the presence of joro toxin (JTX), a
selective blocker of Ca2+-permeable AMPARs31 signiﬁcantly
reduced cell death of week 3 mutant MNs (Fig. 6f). These data
therefore indicate the C9ORF72 mutation is associated with a
higher susceptibility to excitotoxicity due an increase in relative
expression of Ca2+-permeable AMPARs through altered AMPAR
subunit expression.
To determine whether persistent expression of Ca2+-permeable
AMPAR was selective to MNs we next generated cortical neurons
from Con-1, C9-3, and C9-3Δ iPSC lines (Supplementary Fig. 6A,
B, C)32,33. The extent of NASPM block of AMPAR-mediated
currents and the estimated single-channel conductance of
AMPARs in C9-3 cortical neurons, unlike MNs, did not
demonstrate an elevated expression of Ca2+-permeable AMPARs
(Supplementary Fig. 6D, E). Taken together these ﬁndings are
consistent with a MN-speciﬁc cellular pathophysiology caused by
the presence of mutant C9ORF72.
Elevated GluA1 expression in spinal cord of ALS patients. To
evaluate whether ﬁndings in iPSC-derived neurons are
recapitulated in pathological samples from ALS patients, AMPAR
subunit expression was next examined by RNAscope®. Post-
mortem cervical spinal cord and prefrontal cortex (BA9) sections
from three C9ORF72 mutation-carrying ALS patients and three
age-matched controls with no known neurodegenerative disease
were treated with ﬂuorescence in situ hybridization (FISH) probes
against AMPAR subunits and the positive control enzyme PPIB
(Supplementary Fig. 7). In agreement with previous reports of
control samples displayed negligible GluA1 expression in adult
MNs (Fig. 7a)34,35. However, high expression of GluA1 RNA was
observed in the anterior horn neurons of all ALS patients
(Fig. 7b). No difference was found in GluA2, 3, and 4 RNA
expression between ALS and control spinal cord samples
(Fig. 7c). Conversely, in prefrontal cortex sections, expression of
all AMPAR RNA transcripts was similar between ALS and con-
trol samples (Fig. 7c, d). These data conﬁrm in human post-
mortem tissue that the C9ORF72 expansion is associated with an
increase in GluA1 RNA expression in spinal cord MNs but not in
prefrontal cortical neurons.
Discussion
The ability to study human disease-causing mutations under
genetically deﬁned conditions allows causal rather than correla-
tive associations to be ascribed. Using CRISPR technology to
correct the C9ORF72 mutation from three patient-derived iPSC
lines we show that the C9ORF72 mutation is associated with an
increase in GluA1 AMPAR subunit expression, functional
expression of Ca2+-permeable AMPARs, and MN vulnerability to
excitotoxicity. C9ORF72 patient post-mortem tissue also
demonstrates a marked selective upregulation in GluA1 RNA
expression in spinal cord MNs. Both iPSC and pathological data
further reveal that dysregulation of AMPAR expression is not
found in cortical neurons and thus is MN speciﬁc.
There are three major hypotheses as to how C9ORF72 repeat
expansion might be pathogenic: loss of, as yet still unknown,
normal C9ORF72 function, sequestration of RNA binding pro-
teins by RNA foci, and direct toxicity mediated by DPRs25. These
processes are not mutually exclusive. We observed RNA foci and
DPRs in mutant MNs whose expression was reduced or abolished
by gene correction17,18,36. These ﬁndings, consistent with the idea
that RNA-binding proteins sequestered by RNA foci in mutant
C9ORF72 MNs dysregulate RNA metabolism, are supported by
the differential transcriptional ﬁndings between mutant, control,
and corrected MNs revealing an enrichment for genes involved in
RNA metabolism, stress response, and nuclear transport. Col-
lectively our data are consistent with recent studies including
those from human pathological ﬁndings17,18,37–39. Moreover, our
RNA-Seq data reveal new candidate genes that will require future
validation and functional assessment. These include genes
involved in synaptic transmission, protein targeting, and cell–cell
signaling. In view of recent ﬁndings, it would be of interest to
determine whether the increased expression of GluA1 is related to
pathological RNA foci and/or DPRs40. Furthermore, it will be of
considerable interest to study whether other genetic cause of ALS
results in AMPAR dysregulation.
Fig. 4 RNA-Seq analysis on C9ORF72 mutant MNs. a Heat map and dendrogram depicting hierarchical clustering of RNA sequencing reads from controls
(Con-1, Con-2), C9ORF72 mutant (C9-1, C9-3), and C9-3Δ MNs. b Venn diagram depicting identiﬁcation of differentially expressed genes between two
mutant C9ORF72MNs and control MNs. Central intersect represents 165 dysregulated genes compared to both control and gene-corrected MNs. c Scatter
plot showing comparison of transcriptome reads of two independent C9ORF72 mutant MNs and C9-3Δ MNs to controls. Red crosses denote signiﬁcantly
upregulated genes and blue crosses denote signiﬁcantly downregulated genes (p< 0.05, analysis performed using DESeq2). These dysregulated genes in
C9ORF72 mutant MNs are reversed to control levels in C9-Δ MNs. d, e Graph depicting the spread of differentially regulated, upregulated (d), and
downregulated (e) genes in mutant C9ORF72 MNs, red star denotes the levels of GluA1. f, g Gene ontology studies on upregulated (f) and downregulated
genes (g)
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In mixed cultures of neurons and glia derived from C9ORF72
repeat expansion patient iPSCs, MNs ﬁrst exhibit intrinsic
hyperexcitability27, then progress to a hypoexcitable state17. In
contrast, here we have used a modiﬁed protocol for the genera-
tion of highly enriched neuronal cultures that contains negligible
numbers of glial cells24,41. Under these conditions we found no
difference in MN intrinsic excitability. A likely explanation for
the lack of changes in excitability in the present study is that glial-
mediated non-cell autonomous mechanisms underlie changes in
MN function. This hypothesis is supported by recent ﬁndings in
murine cell culture models where exposure of wild-type MNs to
conditioned medium derived from astrocytes expressing mutant
SOD1 alters ion channel function and MN excitability42.
Multiple lines of evidence suggest that dysregulated glutamate
homeostasis plays a role in ALS. These include patient studies
showing reduced expression of glial glutamate transporter,
enhanced CSF glutamate levels, and in vitro and in vivo studies
that reveal selective MN vulnerability to glutamate or AMPAR-
mediated, but not NMDAR, excitotoxicity3,4,43. AMPAR subunit
composition is dynamic and changes in development and is
dysregulated in disease. In early post-natal life, there is a switch
from predominantly Ca2+-permeable to Ca2+-impermeable
AMPARs which reﬂects increased GluA2 containing AMPARs;
the dominant functional determinant of AMPAR-mediated
Ca2+-permeability29. Indeed, this maturation is recapitulated in
this study with control and gene-corrected iPSC MNs showing a
shift from predominant Ca2+-permeable to Ca2+-impermeable
AMPAR from 1 to 3 weeks in culture. In contrast, mutant
C9ORF72MNs display persistent high levels of Ca2+-permeability
at 3 and 5 weeks in culture. The blockade of AMPA-mediated
MN cell death by JTX treatment, a selective blocker of
Ca2+-permeable AMPARs, conﬁrms that C9ORF72 mutation
susceptibility to excitotoxicity is due to an increase in relative
expression of Ca2+-permeable AMPARs. Our ﬁndings are con-
sistent with an earlier study that showed an enhanced vulner-
ability of iPSC-derived mutant C9ORF72 MNs to glutamate-
mediated excitotoxicity18.
One of the proposed mechanisms of MN death in ALS is
through inefﬁcient post-transcriptional editing of the Q/R site
within the GluA2 subunit with the resulting AMPAR becoming
Ca2+-permeable16,44. Our ﬁnding of efﬁcient RNA editing does
not support reduced editing as an explanation for increased
Ca2+-permeability in mutant C9ORF72 MNs and is consistent
with ﬁndings in native neurons and SOD1 familial cases45,46.
Alternative explanations for increased Ca2+-permeability include
disease-related alterations in AMPAR subunit composition.
Experimental evidence in support of this idea is provided by
ﬁndings in the SOD1 model of ALS, although these reports do not
agree on the precise identity of dysregulated AMPAR sub-
units8,10,11,47,48. Against this background, we show multiple lines
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Fig. 5 The C9ORF72 mutation is associated with increased expression of GluA1 AMPAR subunits. a Relative mRNA expression of AMPAR subunits in all
cultures examined at week 3 after differentiation (data represented as mean± s.e.m., Con-1, N= 5; Con-2, N= 6; C9-1, N= 8; C9-1Δ, N= 4; C9-2,
N= 7; C9-2Δ, N= 6; C9-3, N= 7; C9-3Δ, N= 6). Statistical comparisons; one-way ANOVA with uncorrected Fisher’s LSD. Signiﬁcant p-values for GluA1
C9-1 vs. Con-1: 0.0039, C9-2 vs. Con-1: 0.0360, C9-3 vs. Con-1: 0.0503, C9-1 vs. Con-2: 0.0130, C9-2 vs. Con-2: 0.0163, C9-3 vs. Con-2: 0.0385. p-values
for GluA3 C9-1 vs. Con-1: 0.0218, C9-3 vs. Con-1: 0.0017, C9-1 vs. Con-2: 0.0256, C9-3 vs. Con-2: 0.0024. b Representative immunoblot showing elevated
levels of GluA1 in C9ORF72mutant MNs. c Quantiﬁcation of GluA1 protein level in C9ORF72mutant MNs (data represented as mean± s.e.m., Con-1, N= 3;
Con-2, N= 5; C9-1, N= 6; C9-1Δ, N= 3; C9-2, N= 3; C9-2Δ, N= 3; C9-3, N= 6; C9-3Δ, N= 6). d Representative gel picture showing efﬁcient GluA2 Q→R
RNA editing in week 3 cultures across all the lines. Efﬁcient GluA2 RNA editing results in RFLP amplicons of 116 and 66 bp, see also Supplementary Fig. 4B.
Band at 81 bp would be observed if inefﬁcient editing of the GluA2 subunit was present
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of evidence that demonstrate upregulation in the GluA1 AMPAR
subunit in C9ORF72mutant MNs. The maintenance of functional
expression of the GluA1 subunit strongly correlates with an
increased Ca2+-permeable AMPAR identity in our cultures.
Although GluA1 upregulation has previously been reported in the
spinal cord and hippocampus of hSOD1G93A mice11,49, our
study now demonstrates potential functional consequences of
increased GluA1 in an experimental ALS model. Furthermore,
our data demonstrate that mutant C9ORF72 cortical neurons
possess predominantly Ca2+-impermeable AMPARs, indicating
that mutant C9ORF72-dependent increases in Ca2+-permeable
AMPARs are selective to MNs. Moreover, our ﬁndings are con-
sistent with recent reports from C9ORF72 FTD patient iPSC
neurons and post-mortem cortices that also do not show altered
AMPAR subunit transcript regulation37,50. Furthermore, our
earlier report that oligodendrocytes generated from the same
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mutant C9ORF72 patient iPSC lines used in this study express
predominantly Ca2+-impermeable AMPARs further highlights
MN-speciﬁc consequence of the C9ORF72 mutation51. Finally, in
post-mortem studies, we show for the ﬁrst time that mutant
C9ORF72 spinal cord but not cortical neurons show selective
upregulation of GluA1 transcript by quantitative RNAscope
compared to age-matched control samples. We therefore propose
that the mutant C9ORF72-dependent increase in Ca2+-permeable
AMPAR-mediated excitotoxicity is MN speciﬁc.
Importantly, our in vitro and post-mortem data suggest that
GluA1 subunit upregulation may be contributory to selective MN
death in ALS. Notwithstanding our observation of selective
upregulation of GluA1 in post-mortem mutant C9ORF72 spinal
cord MNs, we are unable to determine whether this is causal or a
consequence of a separate disease pathology. It is also important
to note that our study cannot exclude other AMPAR-related
mechanisms that could potentially play a role in mutant
C9ORF72-related MN pathology18. Furthermore, the degree to
which other mechanisms may concurrently contribute to exci-
totoxicity via elevated glutamate levels at synapses, such as
changes in glial glutamate transporter expression remains
unknown52,53.
Our RNA-Seq study uncovered a mutant C9ORF72-associated
increase in GRIA1 (GluA1) expression, which led to the
hypothesis of increased Ca2+-permeable AMPA receptor currents
and elevated vulnerability to AMPAR-mediated excitotoxicity.
However, other genes whose expression are perturbed may also
contribute to this phenotype. Our data also revealed a C9ORF72
mutation-associated reduction in PICK1 expression. PICK1 reg-
ulates the surface trafﬁcking of GluA2-containing AMPARs54,
and so a reduction in its expression may modify the proportion of
GluA2-lacking AMPARs at the surface. Further genes within this
data set may contribute to, or reﬂect other aspects of mutant
C9ORF72-associated cellular phenotypes. For example, we
observe a C9ORF72 mutation-associated increase in HSPB8,
SERP1, and HSP90B1. The small heat shock protein HSPB8/
HSP22 plays a role in protein quality control and is capable of
promoting the clearance of aggregates of C9ORF72 dipeptides, as
well as mutant SOD1 and TDP-4355–57. SERP1 (RAMP4) is
induced by ER stress via a XBP-1-dependent process58 whose role
is to reduce protein stress by stabilizing proteins to facilitate
glycosylation and promote translocation of proteins into the
ER59–61. HSP90B1 (GRP94, GP96) is another ER chaperone
involved in the unfolded protein response (UPR), and a ATF6
target62. Collectively, the induction of these genes point to a
degree of ER stress and activation of the UPR. Conversely,
increased ER Ca2+ levels, elevated GRP78/BiP63, and vulnerability
to tunicamycin-induced ER stress/UPR64 have been observed in
C9ORF72 mutant motor neurons. This may be triggered by the
presence of C9ORF72 dipeptides and/or C9ORF72
hexanucleotide-induced disruption of nucleocytoplasmic trans-
port65 and even be exacerbated by increased GluA2-lacking
AMPARs, since excessive Ca2+ inﬂux can inﬂuence ER stress66.
Also of interest, GluA1 surface expression is known to be pro-
moted by the UPR67, raising the possibility of positive feedback
on excitotoxic signaling.
In summary, this study has combined patient iPSC lines and
CRISPR/Cas9 technologies to demonstrate that the C9ORF72
repeat expansion recapitulates key pathological features of
mutant C9ORF72 ALS and, with C9ORF72 ALS patient post-
mortem material, suggests a possible mechanism for MN vul-
nerability to AMPAR-mediated excitotoxicity.
Methods
Cloning of CRISPR/Cas9 constructs. Cas9 and gRNA were cloned into an
expression plasmid pSpCas9(BB)-2A-GFP (pX458) following a published
protocol68. Web tool (http://crispr.mit.edu) was used to design CRISPR gRNA
sequences and identify potential homologous off-target sites. Sequences of gRNAs
are as follows: gRNA-1 5′-AACTCAGGAGTCGCGCGCTAGGG-3′, gRNA-2
5′-GGCCCGCCCCGACCACGCCCCGG-3′.
Derivation of iPSCs. Dermal ﬁbroblasts from patient and control individuals were
obtained under full Ethical/Institutional Review Board approval at the University of
Edinburgh. Fibroblasts were reprogrammed to iPSCs by either Sendai virus or
retrovirus expressing OCT4, SOX2, C-MYC, and KLF4. iPSCs were maintained in
Matrigel (BD Biosciences)-coated plastic dishes in E8 medium (Life Technologies)
at 37 °C and 5% CO2.
Gene editing of iPSCs. iPSC were dissociated into single-cell suspension using
1 × Accutase (Sigma). 8 × 105 cells were nucleofected with 2 µg each of Cas9-
gRNA1 and Cas9-gRNA2 plasmid using the Amaxa 4D nucleofector system
(program CA137) following the manufacturer’s instructions. Transfected cells were
plated onto Matrigel (BD)-coated dishes in the presence of E8 medium supple-
mented with ROCK inhibitor (10 µM). Upon conﬂuence, cells were dissociated
again into single cells and plated down at low density (2000 cells/10 cm dish) for
clonal analysis. Individual clones were picked and screened for deletion of G4C2
repeats by G4C2 locus PCR and repeat primed PCR using an ABI 3130xl genetic
analyzer.
Repeat primed PCR. The C9ORF72 repeat expansion mutation was conﬁrmed in
both iPSCs and MNs by repeat primed PCR using Qiagen multiplex PCR kit. PCR
components are as follows: 1 ×Multiplex Mastermix, 7% dimethylsulfoxide, 0.6 M
Betaine, 7.6 µM FAM-labeled RP Fw (5′-CTGTAGCAAGCTCTGGAACTCAG-
GAGTCG-3′), 3.6 µM RP Rev: (5′-TACGCATCCCAGTTTGAGACGCCCC
GGCCCCGGCCCCGGCCCC-3′), 11.6 µM Tail Rev (5′-TACGCATCCCAGTTT-
GAGACG-3′), 8 mM 7-deaza-2′-dGTP, and 200 ng DNA. Cycling conditions were
performed as per the manufacturer’s recommendations with annealing tempera-
ture of 68 °C for 15 cycles, followed by 60 °C for a further 20 cycles. PCR products
Fig. 6 Mutant C9ORF72 MNs exhibit Ca2+-permeable AMPARs receptors and greater vulnerability to excitotoxicity. a Sample whole-cell voltage-clamp
recordings conducted at −74mV depicting the block of AMPA (10 μM)-mediated currents (in the presence of cyclothiazide (10 μM)) by Ca2+-permeable
AMPAR-selective blocker NASPM (3 μM) in week 5 MNs derived from a control, mutant C9ORF72, or C9-Δ lines. Scale bars: 5 s, 50 pA. bMean (± s.e.m.)
percentage NASPM block of AMPA currents in all MNs examined at week 1, 3, and 5 (data for week 1/week 3/week 5; Con-1, n= 6/10/6, N= 3/3/1;
Con-2, n= 14/12/6, N= 2/2/2; C9-1, n= 9/9/14, N= 2/1/3; C9-1Δ, n= 5/8/5, N= 2/2/2; C9-2, n= 9/12/12, N= 2/3/3; C9-2Δ, n= 8/10/10,
N= 3/4/4; C9-3, n= 7/11/11, N= 3/3/3; C9-3Δ, n= 10/10/7, N= 3/3/3) after differentiation (statistical comparisons; one-way ANOVA with Bonferroni’s
post hoc test). c Representative non-stationary ﬂuctuation analysis recordings of AMPAR-mediated currents in the AC-current (upper) and DC-current
modes (lower) of week 5 MNs derived from a control, mutant C9ORF72, or the C9-Δ lines. Current-variance plots (bottom right) generated from the
recordings presented were used to derive the γ. Scale bars; 5 s, 40 pA. d Mean estimated AMPAR γ in all lines examined at week 1, 3, and 5 (data week
1/week 3/week 5; Con-1, n= 15/15/12, N= 4/4/3; Con-2, n= 13/15/8, N= 2/2/2; C9-1, n= 10/11/21, N= 2/3/3; C9-1Δ, n= 7/6/8, N= 2/2/2; C9-2,
n= 15/15/13, N= 3/3/2; C9-2Δ, n= 11/12/7, N= 3/3/2; C9-3, n= 12/18/19, N= 4/3/4; C9-3Δ, n= 17/23/8, N= 4/4/2) after differentiation (statistical
comparisons; one-way ANOVA with Bonferroni’s post hoc test). e Representative images of Calcein AM-stained neurons derived from control, C9, and
C9-Δ lines before and after 24-h treatment of AMPA (100 μM) in the presence of cyclothiazide (100 µM). Scale bar: 50 µm. Cyclothiazide is an
AMPAR-selective allosteric potentiator used to prevent rapid AMPAR desensitization. f Mean percentage cytotoxicity of MNs treated with AMPA,
AMPA + JTX, and AMPA + CNQX (data represented as mean± s.e.m., Con-1, N= 6; Con-2, N= 5; C9-1, N= 5; C9-1Δ, N= 5; C9-2, N= 9; C9-2Δ, N= 5;
C9-3, N= 5; C9-3Δ, N= 5) and at least 100 cells per experiment, Greek letter phi denotes signiﬁcant difference (two-way ANOVA with uncorrected
Fisher's LSD) in cell death with JTX treatment when compared to AMPA treatment
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were separated on an ABI 3130xl analyzer (Life Technologies) and data were
analyzed using GeneMarker software (Soft Genetics).
A G4C2 ﬂanking PCR for screening targeted clones was also performed using
Qiagen multiplex PCR kit. The PCR reaction was set up as per manufacturer’s
guide lines using the following primers G4C2 Fw: 5′-CAAGGAGGGAAACAA
CCG-3′ G4C2 Rev: 6-FAM- 5′-GGAAAGCAAGGAAGAGGC-3′. PCR products
were separated on an ABI 3130xl analyzer (Life Technologies) and data were
analyzed using GeneMarker software (Soft Genetics).
Southern blot. Southern blot analysis was used to analyze the C9ORF72 repeat
expansion mutation as described69. DNA was isolated using Wizard® genomic
DNA puriﬁcation kit (Promega). 20 µg of DNA was digested overnight with Xba
endonuclease, separated on a 0.8% agarose gel electrophoresis, gel was subsequently
depurinated, denatured, and transferred overnight on to a positively charged nylon
membrane (Roche). The membrane was UV cross-linked and hybridized overnight
at 47 °C with a digoxigenin (DIG)-labeled PCR probe. PCR probe was synthesized
from genomic DNA using PCR DIG probe synthesis kit (Roche) using following
primers South Fw: 5′-CTTGCAGATCAAAAGGCACA-3′ and South Rev: 5′-
TTGACGCACCTCTCTTTCCT-3′. Following hybridization, membrane was
washed and labeled with anti-DIG antibody and developed using CDP-Star reagent
as per manufacturer’s recommendation (Roche).
MN differentiation. MN differentiation from iPSCs was performed using estab-
lished protocol24 with minor modiﬁcations. iPSCs were dissociated into single cells
using 1 × Accutase, 2 × 106 iPSCs were neuralized as a suspension culture using SB-
431542 (20 µM), LDN-193189 (0.1 µM), and CHIR-99021 (3 µM) in N2/B27 media
(0.5 × Neurobasal, 0.5 × Advanced DMEM/F12, 1 × Antibiotic-Antimycotic, 1 ×
Glutamax, 100 µM beta-mercaptoethanaol, 1 × B27, 1 × N2, and 10 µM ascorbic
acid). On day 2, neural spheres were simultaneously patterned to spinal cord
identity by treating with retinoic acid (RA, 0.1 µM) and smoothened agonist (SAG,
500 nM) along with SB-431542, LDN-193189, and CHIR-99021 in N2/B27 media
for additional 5 days. On day 7, spheres continued to be cultured in RA and SAG
and, also, brain-derived neurotrophic factor (BDNF, 10 ng/ml) in N2/B27 media to
generate MN progenitors. On day 9, MN progenitors were cultured in the previous
media in addition to DAPT (10 µM) for additional 5–7 days. At day 14–16, MN
spheres were dissociated using 0.05% Trypsin-EDTA and plated on to a poly-
ornithine, laminin (5 µg/ml), ﬁbronectin (10 µg/ml), Matrigel (1:20)-coated dishes.
Dissociated MNs were cultured in NB media (1 × Neurobasal, 1 × Glutamax,
1 × non-essential amino acids, 100 µM beta-mercaptoethanol, 1 × B27, 1 × N2, RA
(1 µM), ascorbic acid (2.5 µM), BDNF (10 ng/ml), glial-derived neurotrophic factor
(10 ng/ml), ciliary neurotrophic factor (10 ng/ml), insulin-like growth factor (10
ng/ml)). Cells were treated with Uridine (1 µM)/5-ﬂuoro-2′-deoxyuridine (U/FDU)
on day 1 to remove residual proliferating cells. Media was changed every 2–3 days.
Quantitative RT-PCR. qPCRs were performed following previously optimized
protocol32. Brieﬂy, RNA from week-1 and week-3-old MNs were isolated using
RNeasy kit (Qiagen). cDNA was synthesized from 250 ng of total RNA using
DyNAmoTM cDNA synthesis kit (Thermo Scientiﬁc). Real-time quantitative PCR
reactions were set up using DyNAmo ColorFlash SYBR Green qPCR kit (Thermo
Scientiﬁc) and performed on CFX96 system (BioRad). Primers (forward and
reverse) and annealing temperature used in this study are as follows: GRIA1:
5′-TGCTTTGTCGCAACTCACAGA-3′, 5′-GGCATAGACTCCTTTGGAG
AAC-3′, 64 °C; GRIA2: 5′-CATTCAGATGAGACCCGACCT-3′, 5′-GGTATG-
CAAACTTGTCCCATTGA-3′, 58 °C; GRIA3: 5′-ACCATCAGCATAGGTG
GACTT-3′, 5′-GGTTGGTGTTGTATAACTGCACG-3′, 58 °C; GRIA4:
5′-TTCCGAGCAGCGTGCAAATA-3′, 5′-GCATTGGGGCTGGTGTTATGA-3′,
58 °C; C9orf72: 5′-TGTGACAGTTGGAATGCAGTGA-3′, 5′-GCCACTTAAAG-
CAATCTCTGTCTTG-3′, 59 °C; ACTB: 5′-GTTACAGGAAGTCCCTTGCC
ATCC-3′, 5′-CACCTCCCCTGTGTGGACTTGGG-3′, 59 °C.
RNA sequencing. Total RNA from iPSC-derived MNs was assessed for quality
(Agilent Bionalyzer) and quantity (Invitrogen Qubit) before library preparation.
Illumina libraries were prepared from 1 µg of total RNA using TruSeq RNA Sample
Prep Kit v2 with a 10 cycle enrichment step as per the manufacturer’s recom-
mendations. Final libraries were pooled in equimolar proportions before Illumina
sequencing on a HiSeq 2500 platform using 75 base paired-end reads.
Reads were mapped to the primary assembly of the human (hg38) reference
genome contained in Ensembl release 83. Alignment was performed with STAR,
version 2.4.0i70. Tables of per-gene read counts were generated from the mapped
reads with featureCounts version 1.4.6-p271. Differential expression analysis was
then performed using DESeq272 (R package version 1.10.0).
Immunocytochemistry. Cells were cultured depending on the experiment, washed
once with PBS to remove media components, and ﬁxed with 4% PFA for 20 min at
room temperature. Cells were washed three times with PBS and blocking buffer
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Fig. 7 AMPAR subunit expression in post-mortem spinal cord of healthy patients and ALS patients with C9ORF72 repeat expansion. a Representative
RNAscope® images showing the expression of AMPAR GluA1—four transcripts in the anterior horn of cervical spinal cord sections from an ALS patient
(C9ORF72) and an age-matched healthy patient and reveals increased expression of GluA1 in ALS patient sample. Scale bar, 25 µm. b Quantiﬁcation of the
mean± s.e.m. expression levels of AMPAR transcripts in spinal cord samples from three independent patients and controls. Note the lack of GluA1
transcript expression in control spinal cord samples and strong expression in patient samples. c Representative RNAscope images showing the expression
of AMPAR GluA1—four transcripts in the prefrontal cortex from an ALS patient (C9ORF72) and an age-matched healthy patient. Scale bar, 25 µm. d
Quantiﬁcation of the mean± s.e.m. expression levels of AMPAR transcripts in prefrontal cortex samples from three independent patients and controls
showing equivalent expression of all transcripts
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containing 3% goat serum and 0.25% Triton X-100 in TBST (TBS-Tween) sub-
sequently added for 30 min. Primary antibodies diluted in blocking buffer were
then added and incubated overnight at 4 °C. Cells were then washed three times
with TBS-Tween, and corresponding secondary antibodies coupled with ﬂuor-
ophores were added and incubated at room temperature for 1 h. Coverslips were
washed and mounted on glass slides with FluorSaveTM reagent and imaged using
Zeiss observer Z1. Images for cell count and neurite outgrowth were analyzed using
ImageJ. Antibodies used in this study are as follows: MAP2 1:1000 (Sigma M9942),
SMI312 1:1000 (Abcam ab24574), Tau 1:2000 (DAKO A0024), ISL1/2 1:50 (DSHB
39.4D5), ChAT 1:250 (EMDMillipore AB144P).
Western blot analysis. MNs were cultured for 3 weeks and lysed directly with
2 × Laemmli buffer (125 mM Tris HCl pH 6.8, 4% SDS, 10% β−mercaptoethanol,
20% glycerol, and 0.004% bromophenol blue) and boiled for 10 min at 99 °C.
Proteins were then run on a SDS-Poly acrylamide gel electrophoresis, blotted onto
a nitrocellulose membrane. Membranes were then probed with respective primary
and secondary antibodies and developed using ECL or ECL Advance (GE
Healthcare). Blots were scanned and densitometry analysis was performed using
ImageJ. Antibodies used GAPDH (1:5000), GluA1 (1:1000), C9ORF72 (1:2000).
RNA ﬂuorescence in situ hybridization. FISH analysis was performed using an
Alexa546-conjugated (GGCCCC)4 oligoneucleotide probe (IDT). Brieﬂy, cells on
glass coverslips were ﬁxed in 4% paraformaldehyde for 15 min, permeabilized in
70% ethanol at 4 °C overnight, incubated with 50% formamide diluted with 2X SSC
for 10 min at room temperature and hybridized for 2 h at 45 °C with the probe
(0.16 ng/µl) in hybridization buffer consisting of 50% formamide, 10% dextran
sulfate, yeast transfer RNA (1 mg/ml), salmon sperm DNA (1 mg/ml). The cells
were washed twice with 50% formamide diluted with 2 × SSC for 30 min at 37 °C
and once with 2X SSC at room temperature for 30 min. Immunocytochemistry was
performed as described above.
Electrophysiology. Experiments investigating excitability were performed as pre-
viously described26. In short, whole-cell patch-clamp recordings were made in the
current-clamp mode to determine ﬁring properties of MNs. Recordings were
performed using electrodes ﬁlled with internal pipette solution contained (in mM):
140 potassium methane-sulfonate, 10 NaCl, 1 CaCl2, 10 HEPES, 1 EGTA, 3 Mg2-
ATP, and 0.4 Na3-GTP, pH 7.2–7.3 (adjusted with KOH; osmolarity adjusted to
300 mOsm with sucrose). Cells were bathed in an extracellular recording com-
prising (in mM): 127 NaCl, 3 KCl, 2 CaCl2, 1 MgCl2, 26 NaHCO3, 1.25 NaH2PO4,
and 10 D-glucose (equilibrated with 95% O2 and 5% CO2, pH 7.45; osmolarity,
310 mOsm). Recordings were low-pass ﬁltered at 4 kHz and digitized at 50 kHz
using pClamp software (Axon Instruments). F–I relationships were generated by
recording the responses to a series of 1 s duration current steps of 5–65 pA (10 pA
increments).
For other electrophysiological experiments, recordings were performed as
decribed33 using electrodes ﬁlled with (in mM): 155 K-gluconate, 2 MgCl2, 10 Na-
HEPES, 10 Na-PiCreatine, 2 Mg2-ATP, and 0.3 Na3-GTP, pH 7.3, 300 mOsm. Cells
were bathed in an extracellular recording comprising (in mM): 152 NaCl, 2.8 KCl,
10 HEPES, 2 CaCl2, 10 glucose, pH 7.3, 320–330 mOsm. Current and voltage
measurements were typically low-pass ﬁltered online at 2 kHz, digitized at 10 kHz
and recorded to computer using the WinEDR V2 7.6 Electrophysiology Data
Recorder (J. Dempster, Department of Physiology and Pharmacology, University of
Strathclyde, UK; www.strath.ac.uk/Departments/PhysPharm/).
Non-stationary ﬂuctuation analysis of slowly rising whole-cell currents evoked
by AMPA were used to estimate the AMPAR unitary single-channel current. The
analysis of AC and DC currents was performed as described previously in detail73
with the exception that the AC-coupled signal was ﬁltered with a 1–1200 Hz band-
pass frequency.
All experiments were carried out at room temperature. Patch electrodes were
manufactured from borosilicate glass to have resistances of 3–6MΩ. Recordings
were made with a series resistance less than 25MΩ. Reported potential values are
corrected for liquid junction potential.
Excitotoxicity assay. MNs (25,000 per well of a 96-well plate) were cultured for 1
or 3 week/s. Before the assay was performed, cells were further cultured overnight
with minimal essential media containing neurobasal, B27, and N2. Live cells were
labeled with 4 µM Calcein-AM (Invitrogen) for 5 min and imaged using Zeiss
Observer Z1. Cells were then treated in the presence of cyclothiazide (100 µM) with
either AMPA (100 µM) or AMPA/CNQX (30 µM) or AMPA/JTX (1 µM) for 24 h.
Following treatment, cells were labeled again with Calcein AM and reimaged. Cell
counts before and after treatment were analyzed using ImageJ.
Human post-mortem tissue analysis. Formalin-ﬁxed parafﬁn-embedded cervical
spinal cord and prefrontal cortex (BA9) from three ALS patients carrying the
C9ORF72 repeat expansion and three age and sex-matched controls were sectioned
at 5-μm thickness on to superfrost slides. BaseScope reagents (Advanced Cell
Diagnostics) were used as per manufacturer’s guidelines according to the original
protocol74. In brief, following deparaﬁnisation, tissue was incubated with hydrogen
peroxide for 10 min at room temperature and target antigen retrieval was
performed by submerging slides in BaseScope 1 × target retrieval reagent at 99 °C in
a Braun Multiquick FS 20 steamer for 15 min. The tissue was then permeabilised
using BaseScope protease III at 40 °C for 30 min. Probe hybridization was then
performed by incubating the slides with four drops of custom-designed BaseScope
probe for AMPAR subunits, negative control probe (DapB) or positive control
(PPIB) probe for 2 h at 40 °C. Following successive probe ampliﬁcation steps,
transcripts were detected using the BaseScope RED detection kit and slides were
counterstained using 50% Gills haematoxylin and 0.02% ammonium water. The
slides were then cleared in xylene and mounted with a 24 × 50 mm coverslip using
two drops of VectaMount mounting medium. Sections were then imaged at 80×
magniﬁcation on a NanoZoomer and relative number of transcripts was quantiﬁed
by counting the dots observed in the cell manually by two independent neuro-
pathologist. Three random ﬁelds were chosen and ten cells from each ﬁeld were
counted (in total 30 cells per post-mortem sample) and averaged for each patient.
Data were plotted as mean number of transcripts (dots per cell) per post-mortem
sample.
Data analysis. Statistical analysis was performed using GraphPad Prism software.
Data are represented as mean ± s.e.m. *p< 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001, one-way ANOVA with Bonferroni’s multiple comparisons test or uncor-
rected Fisher’s LSD test.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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